Lanzostad

Lansoprazole, the active ingredient in Lanzostad, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Helicobacter pylori infection in adult patients. GNH USA supplies Lanzostad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lanzostad, a proton pump inhibitor, is indicated for several acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief of heartburn and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal healing and reduces recurrence of lesions. - Peptic ulcer disease: promotes ulcer closure and prevents recurrence by suppressing gastric acid. - Helicobacter pylori eradication: used in combination therapy to increase eradication rates by creating a less acidic environment.

Lanzostad may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually self‑limiting. - Nausea: occasional feeling of stomach upset. - Abdominal pain: mild cramping or discomfort. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hypomagnesemia: low serum magnesium with prolonged use. - Bone fractures: increased risk with long‑term therapy. - Interstitial nephritis: kidney inflammation presenting with renal impairment. - Hepatotoxicity: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function assessment: adjust use in patients with severe renal impairment. - Magnesium monitoring: check serum magnesium during prolonged treatment. - Long‑term use evaluation: limit duration unless clinically justified. - Elderly patients: use with caution due to higher fracture risk. - Drug interaction review: assess concomitant medications that may affect acid suppression. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lanzostad can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Atazanavir (HIV protease inhibitor): reduced absorption leading to therapeutic failure. - Clopidogrel: decreased activation, potentially reducing antiplatelet effect. - Methotrexate (high dose): increased serum levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentration, monitor levels. - Ketoconazole and other azole antifungals: reduced absorption, consider alternative agents. - Warfarin: possible increase in INR, monitor coagulation parameters. - Ticagrelor: may reduce antiplatelet activity, assess clinical response.